Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 15/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17031835 | 0.89 | ADRA1D (0.39) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL19490442 | 0.85 | ADRA1D (0.45) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL17033295 | 0.80 | CA1 (0.56) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL19352873 | 0.78 | ADRA1D (0.32) | ADRA1DCA1CA2 | |
| SCHEMBL10192230 | 0.78 | ADRA1D (0.36) | ADRA1DALDH1A1 | |
| SCHEMBL17050355 | 0.76 | ADRA1D (0.46) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL20992167 | 0.76 | ADRA1D (0.46) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL19234732 | 0.76 | ADRA1D (0.44) | ADRA1DCA1CA2ADRA1AADRA1B | |
| SCHEMBL19068824 | 0.76 | CA1 (0.32) | ADRA1DCA1CA2 | |
| SCHEMBL19962310 | 0.75 | PTGDR2 (0.33) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | ADRA1D 1137/4885CA1 4833/4885CA2 4462/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | ADRA1D 415/4885CA1 3399/4885CA2 3284/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | ADRA1D 736/4885CA1 2078/4885CA2 3629/4885 |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | ADRA1D 725/4885CA1 2728/4885CA2 3823/4885 |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | ADRA1D 415/4885CA1 3399/4885CA2 3284/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | ADRA1D 991/4885CA1 4751/4885CA2 4184/4885 |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | ADRA1D 185/4885CA1 4208/4885CA2 4286/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | ADRA1D 779/4885CA1 4739/4885CA2 4133/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ADRA1D 725/4885CA1 2728/4885CA2 3823/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | ADRA1D 814/4885CA1 3111/4885CA2 4172/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | ADRA1D 814/4885CA1 3111/4885CA2 4172/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | ADRA1D 268/4885CA1 4302/4885CA2 4252/4885 |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | ADRA1D 736/4885CA1 2078/4885CA2 3629/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ADRA1D 678/4885CA1 1983/4885CA2 3506/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | ADRA1D 725/4885CA1 2728/4885CA2 3823/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | ADRA1D 1133/4885CA1 2493/4885CA2 3626/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | ADRA1D 1485/4885CA1 554/4885CA2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.